- |||||||||| Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir, Tagrisso (osimertinib) / AstraZeneca
PK/PD data, Journal: Population Pharmacokinetics of Osimertinib in Patients With Non-Small Cell Lung Cancer. (Pubmed Central) - Apr 28, 2025
Visual predictive checks showed that the final model validated osimertinib steady-state PK for adjuvant treatment. PopPK modeling indicated that osimertinib dose adjustment is not required for patients' age, sex, body weight, race, smoking status, or line of therapy, confirming that a fixed 80?mg once-daily dose is optimal for osimertinib.
- |||||||||| Xefo (lornoxicam) - Old API Wind / down, Takeda, Bystolic (nebivolol) / Menarini, AbbVie
Preclinical, Journal: In vitro-in vivo scaling of cytochrome P450-mediated metabolic clearance using a relative activity factor approach. (Pubmed Central) - Apr 28, 2025
These insights may guide antipsychotic choice and improve management of metabolic side effects. We selected multiple probe substrates for CYP1A2 (caffeine, tizanidine, phenacetin), CYP2C9 ((S)-acenocoumarol, glimepiride, lornoxicam, tolbutamide, (S)-warfarin), CYP2C19 ((S)-lansoprazole, omeprazole, pantoprazole), CYP2D6 (desipramine, metoprolol, nebivolol, tolterodine), and CYP3A4 (alprazolam, felodipine, midazolam, nisoldipine, sildenafil, triazolam) to calculate the representative RAF value for each P450 isoform based on the in
- |||||||||| mefloquine / Generic mfg.
PK/PD data, Preclinical, Journal: CYP1A2 contributes to the metabolism of mefloquine: Exploration using in (Pubmed Central) - Apr 28, 2025
Here, we identify CYP1A2 as a key enzyme involved in mefloquine metabolism and use physiologically-based pharmacokinetic modeling to demonstrate the contribution of this route to interactions with mefloquine. The in
- |||||||||| ondansetron intravenous / Generic mfg., cisplatin / Generic mfg.
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Chemo-embolization for Head and Neck Cancer (clinicaltrials.gov) - Apr 28, 2025
P2, N=0, Withdrawn,
The in N=48 --> 0 | Trial completion date: Jan 2029 --> May 2030 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jan 2028 --> May 2029
- |||||||||| amisulpride / Generic mfg., quetiapine / Generic mfg.
Journal: Photodegradation of psychotropic medications: Impact on efficacy, safety, and drug properties. (Pubmed Central) - Apr 27, 2025
However, some of the photocompounds exhibit lower predicted binding affinities when interacting with those receptors compared to their parent compounds, indicating a possible loss of function. These findings emphasize the need for further investigation into the effects and safety of drug photoproducts, particularly in the context of long-term pharmacotherapy.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Journal: Effects of Botulinum Toxin A on Condylar Subchondral Bone Mass. (Pubmed Central) - Apr 27, 2025
the inclusion of fluoxetine and ketoprofen as priority compounds in future risk assessments. Botox A induces a significant reduction in condylar subchondral bone mass in rats during the early post-injection period, with subsequent time-dependent recovery.
- |||||||||| dihydroergotamine intranasal (STS101) / Shin Nippon Biomedical Labs
Journal: Transitioning to healthy and sustainable diets has higher environmental and affordability trade-offs for emerging and developing economies. (Pubmed Central) - Apr 27, 2025
In this study, we project changes in water use, dietary quality, and food affordability under four dietary scenarios (including Mediterranean diet, the EAT-Lancet diet, the Healthy US-Style diet, and Vegetarian diet), assessing the potential implications at the country level from 2020 to 2070...However, in the initial phases, increased food demand escalated water use and worsened food affordability, especially in emerging and developing economies, with the maximum average deterioration being 2.62% and 13.06%, respectively. These highlight the need for long-term planning and financial support to ensure successful global transitions.
- |||||||||| fluoxetine / Generic mfg.
Journal: Three-Dimensional Electrosorption for Pharmaceutical Wastewater Management and Sustainable Biochar Regeneration. (Pubmed Central) - Apr 27, 2025
The adsorption capacity of a biochar (BC) obtained from pine wood residues was evaluated for its ability to remove two pharmaceuticals: fluoxetine (FLX) and sulfamethizole (SMZ)...Consecutive cycles of BC use were performed through desorption and electro-regeneration techniques to test its capacity for reuse, and it was observed that application in the 25 mA electric field increased the useful life of the material. Finally, the effect of ionic strength was studied, highlighting that the presence of ions did not significantly affect the efficiency of SMZ removal, although a slight increase was observed at a high ion concentration, probably due to a salinization effect.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Review, Journal: Why Dosing Matters: A Closer Look at the Dose-Response Relationship With OnabotulinumtoxinA. (Pubmed Central) - Apr 27, 2025
Understanding these binding characteristics can aid in optimizing LUR's clinical application and predicting possible interactions with other biomolecules. Appropriate dosing of onabotulinumtoxinA is essential for maximizing benefit and ensuring patient satisfaction.
- |||||||||| Review, Journal: Induction Treatment for HIV-Associated Cryptococcal Meningitis: Where Have We Been and Where Are We Going? (Pubmed Central) - Apr 27, 2025
Adjunctive medications, such as dexamethasone, tamoxifen, and sertraline, have proven ineffective or harmful in clinical trials. This review underscores the ongoing challenges in cryptococcal meningitis treatment and the need for continued research to improve patient outcomes, tracing the evolution from past monotherapy approaches to current combination strategies while exploring future directions.
- |||||||||| clozapine / Generic mfg.
Journal: Fabricating Oral Disintegrating Tablets Without Disintegrant Using Powder-Based 3D Printing. (Pubmed Central) - Apr 27, 2025
This study focused on using powder-based 3D printing to fabricate clozapine-based ODTs...Scanning Electron Microscopy (SEM) analysis revealed a porous structure in 3D-printed tablets, with a porosity of 48.97% (over two times higher than that of compressed tablets as determined by mercury injection meter). Collectively, this finding demonstrates the feasibility of fabricating highly hydrophilic and non-distensible ODTs without disintegrants using powder-based 3D printing.
- |||||||||| quetiapine / Generic mfg.
Review, Journal: The Role of Quetiapine in Treating Delirium in Critical Care Settings: A Narrative Review. (Pubmed Central) - Apr 27, 2025
One of the main challenges is the heterogeneity of patient populations included in randomized trials, making it difficult to determine whether specific subgroups may benefit more from treatment. This narrative review explores the pharmacological properties of quetiapine, its potential role in managing ICU delirium, and the current state of evidence regarding its safety and effectiveness.
- |||||||||| Review, Journal: Carbon Materials in Voltammetry: An Overview of Versatile Platforms for Antidepressant Drug Detection. (Pubmed Central) - Apr 27, 2025
Moreover, the combination of voltammetric approaches with the unique characteristics of carbon and its derivatives has led to the development of powerful electrochemical sensing tools for detecting antidepressant drugs, which are highly desirable in healthcare, environmental monitoring, and the pharmaceutical industry. In this review, carbon-based materials, such as glassy carbon and boron-doped diamond, and a wide spectrum of carbon nanoparticles, including graphene, graphene oxides, reduced graphene oxides, single-walled carbon nanotubes, and multi-walled carbon nanotubes were described in terms of the sensing performance of agomelatine, alprazolam, amitriptyline, aripiprazole, carbamazepine, citalopram, clomipramine, clozapine, clonazepam, desipramine, desvenlafaxine, doxepin, duloxetine, flunitrazepam, fluoxetine, fluvoxamine, imipramine, nifedipine, olanzapine, opipramol, paroxetine, quetiapine, serotonin, sertraline, sulpiride, thioridazine, trazodone, venlafaxine, and vortioxetine.
- |||||||||| fentanyl citrate / Generic mfg., nefopam / Generic mfg.
Journal: Effects of Nefopam on Postoperative Analgesia in Operating Room-Extubated Patients Undergoing Living Donor Liver Transplantation: A Propensity Score-Matched Analysis. (Pubmed Central) - Apr 27, 2025
These findings indicate that nefopam offers effective early analgesia and an opioid-sparing effect in LDLT recipients undergoing OR extubation, suggesting its clinical utility as a component of multimodal analgesia in this high-risk group. Although the reduction in opioid use did not translate into a decreased incidence of opioid-related complications, the favorable safety profile and analgesic efficacy of nefopam support further investigation through prospective trials to define its role in enhanced recovery protocols for OR-extubated LDLT recipients.
- |||||||||| Review, Journal, Monotherapy: Pharmacological Monotherapy for Depressive Disorders: Current and Future-A Narrative Review. (Pubmed Central) - Apr 27, 2025
Brexanolone and zuranolone are effective in postpartum depression (PPD), but the effect size of zuranolone in MDD as monotherapy or adjunctive therapy was very small...NMDA receptor antagonists and neurosteroid antidepressants will play a bigger role with the improvement of accessibility. Psychedelics may become a game changer if phase III studies validate their efficacy and safety in depressive disorders.
- |||||||||| Review, Journal: Novel and Emerging Treatments for Agitation in Schizophrenia and Bipolar Disorder. (Pubmed Central) - Apr 27, 2025
Other emerging treatments such as gabapentin, pregabalin, and ketamine show promise in addressing agitation in specific contexts, including comorbid conditions and treatment-resistant cases...They also face ethical concerns, including the chance of misuse or abuse, as well as regulatory barriers, as they lack FDA approval and their legality changes between states. This review underscores the clinical, practical, and ethical considerations in advancing care for agitated patients, paving the way for more effective and compassionate management strategies in psychiatric settings.
- |||||||||| fluoxetine / Generic mfg.
Journal: Rinsenoside Rg1 and its involvement in Hippo-YAP signaling pathway alleviating symptoms of depressive-like behavior. (Pubmed Central) - Apr 27, 2025
Presently, sixty 6-8 week-old male C57BL/6 mice were selected and randomly allocated to control, chronic restraint stress (CRS), CRS and low G-Rg1 administration (CRS?+?L-Rg1), CRS and high G-Rg1 administration (CRS?+?H-Rg1), and CRS and fluoxetine administration (CRS?+?FLX) groups...Importantly, the changes in synaptic plasticity and apoptosis were thoroughly investigated to determine the role of chronic G-Rg1 in the forementioned processes. In conclusion, chronic G-Rg1 played an important neuroprotective role in either CRS mice or Cort-treated cells associated with the inhibition of Hippo-YAP signaling pathway, which was the core part of decreasing neuronal apoptosis and enhancing synaptic plasticity.
- |||||||||| paroxetine / Generic mfg.
Journal: A step closer to optimal paroxetine dosing: what is next? (Pubmed Central) - Apr 27, 2025
Overall, QTc assessment using telemetry is the more sensitive and consistent technique and is a model sufficiently sensitive to supplement clinical QTc assessment. No abstract available
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Review, Journal: Unraveling the Complexity of Alzheimer's Disease: Insights into Etiology and Advancements in Treatment Strategies. (Pubmed Central) - Apr 27, 2025
The various pathophysiological pathways that underlie Alzheimer's disease and how it is managed by conventional medication therapy, including current exploratory therapeutic options, are covered in this review article. Innovative, beneficial policies are essential to determine and progress therapeutic molecules to defend against AD.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Review, Journal: Expert Opinions on Best Practices for Overactive Bladder Management with onabotulinumtoxinA. (Pubmed Central) - Apr 27, 2025
Subsequent treatments should be regularly scheduled at six-month intervals with the option of re-treating earlier if symptoms return, but no sooner than 12 weeks. For office intravesical onabotulinumtoxinA procedures, optimization of the patient experience by the physician and their staff, starting with the initial visit through the post-treatment follow-up, is key to long-term patient compliance.
- |||||||||| Dysport (abobotulinumtoxinA) / Ipsen, Xeomin (incobotulinumtoxinA) / Merz Pharma, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Retrospective data, Journal: Protocol and Demographics of the RELY-CD Study: Assessing Long-Term Clinical Response to Botulinum Neurotoxin in Cervical Dystonia. (Pubmed Central) - Apr 27, 2025
The primary endpoint was a comparison of a clinically meaningful worsening in DEff in treatment year 7 compared to year 2 between complex-free and complex-containing botulinum neurotoxin type A. The RELY-CD study provides unique insights into long-term treatment patterns, clinical resistance phenomena, and the implications of formulation differences on treatment outcomes, addressing a critical gap in the literature on real-world botulinum neurotoxin type A application. The study methodology, including the definition and calculation of the novel DEff, as well as clinical baseline characteristics, are presented.
- |||||||||| Jeuveau (prabotulinumtoxinA-xvfs) / AEON Biopharma, Dysport (abobotulinumtoxinA) / Ipsen, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Review, Journal: Botulinum Toxin in the Treatment of Hair and Scalp Disorders: Current Evidence and Clinical Applications. (Pubmed Central) - Apr 27, 2025
BoNT-A and B showed consistent efficacy in treating craniofacial hyperhidrosis with minimal side effects. Additional scalp conditions may benefit from BoNT therapy, but the evidence is limited, and larger, controlled studies are needed to better understand BoNT's clinical value in these conditions.
- |||||||||| botulinum toxin A (MBA-P01) / Medytox, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Clinical, P3 data, Journal: Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19. (Pubmed Central) - Apr 27, 2025
The limitations of this study include the predominance of female participants and the exclusive enrollment of Korean patients. MBA-P01 is expected to be clinically useful in terms of the efficient and safe reduction of glabellar wrinkles, which will provide patients with additional treatment options.
- |||||||||| phenytoin / Generic mfg., ketamine / Generic mfg., memantine / Generic mfg.
Preclinical, Journal: A mouse model of GRIN2D developmental and epileptic encephalopathy recapitulates the human disease. (Pubmed Central) - Apr 27, 2025
Conversely, memantine (10 mg/kg) and phenytoin (30 mg/kg) demonstrated a small corrective effect on ECoG properties. Together, Grin2d mutant mice recapitulate key phenotypes of patients with pathogenic GRIN2D variants, including unique, abnormal brain oscillations, which may serve as a biomarker for quantifying drug responses and guiding future research efforts.
- |||||||||| Review, Journal: Pharmacologic Treatment of Irritable Bowel Syndrome with Predominant Constipation (Pubmed Central) - Apr 27, 2025
Highly selective 5-HT4 agonists, such as prucalopride, accelerate gastrointestinal and colonic transit and improve stool frequency and consistency without increasing the cardiovascular risks raised in earlier agents such as tegaserod...These pharmacology agents have shown efficacy and safety in clinical studies, but drug availability, adverse effects, and variable patient responses are still challenging. Effective strategies to manage IBS-C require a personalized approach, considering the patient's symptom profile, treatment goals, and safety concerns.
- |||||||||| Review, Journal: Treatment of Irritable Bowel Syndrome with Predominant Diarrhea (Pubmed Central) - Apr 27, 2025
Selective serotonin receptor antagonists, such as ramosetron, have benefits in symptom control, particularly in male patients...Personalized treatment approaches are essential because IBS-D presents a wide spectrum of symptoms. Clinicians should tailor therapeutic plans based on individual patient characteristics, balancing the benefits and risks of each intervention to optimize symptom control and improve the quality of life.
|
